The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- Forget MannKind Corporation; Here Are 3 Better Biotech Stocks
- Why Shares of Eagle Pharmaceuticals Inc. Ripped Higher
- 3 Biotech Stocks to Buy in February
- An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
- Medical Marijuana Goes Wall Street
- Are There Any Marijuana Stocks to Buy in 2015?